Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

20.30USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$20.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
463,280
52-wk High
$23.50
52-wk Low
$5.47

Select another date:

Mon, Feb 5 2018

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

Select another date: